Brief: Gyre Therapeutics Announces NMPA Acceptance Of New Drug Application For F351 (Hydronidone)
12/05/2026 22:32
May 12 (Reuters) - Gyre Therapeutics Inc GYRE.O: GYRE THERAPEUTICS ANNOUNCES NMPA ACCEPTANCE OF NEW DRUG APPLICATION FOR F351 (HYDRONIDONE) FOR CHB-INDUCED LIVER FIBROSIS TREATMENT GYRE THERAPEUTICS: PLANS TO FILE IND APPLICATION IN U.S. BY 2026 END; IF IND BECOMES EFFECTIVE, TO INITIATE PHASE 2 CLINICAL TRIAL Source text: ID:nGNX7Gvhyj Further company coverage: GYRE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gyre Therapeutics
See all newsBrief: Gyre Therapeutics - Enters Employment Agreement With Ying Luo As CEO - SEC Filing
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes